Role of Platelet-Activating Factor and Hypoxia in Persistent Pulmonary Hypertension of the Newborn — Studies with Perinatal Pulmonary Vascular Smooth Muscle Cells by Hanouni, Mona et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 17
Role of Platelet-Activating Factor and Hypoxia in
Persistent Pulmonary Hypertension of the Newborn —
Studies with Perinatal Pulmonary Vascular Smooth
Muscle Cells
Mona Hanouni, Amy M. McPeak,
Stephen M. Douglass, Rebecca Davis,
Shaemion McBride and Basil O. Ibe
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/60728
Abstract
Platelet-activating factor (PAF) plays an important physiological role of maintaining
a high vasomotor tone in fetal pulmonary circulation. At birth, endogenous vasodi‐
lators such as nitric oxide and prostacyclin are released and facilitate pulmonary
vasodilation via cAMP-dependent protein kinase (cAMP/PKA) and cGMP-dependent
protein kinase (cGMP/PKG) pathways. Interaction between the cyclic nucleotides and
PAF receptor (PAFR)-mediated responses in pulmonary arterial smooth muscle is not
well understood. To further understand the interactions of PAF-PAFR pathway and
the cyclic nucleotides in ovine fetal pulmonary arterial smooth muscle cells
(FPASMC), effects of cAMP and cGMP on PAFR-mediated responses in pulmonary
arterial smooth muscle cells (PASMC) were studied. Ovine FPASMC were incubated
with 10μM cAMP or cGMP in normoxia (5% CO2 in air, pO2~100 Torr) or hypoxia (2%
O2, 5% CO2, pO2~30-40 Torr). Proteins were prepared and subjected to Western
blotting. Effect of cell permeable cAMP and cGMP on PAFR binding was also studied
and effect of cAMP on cell proliferation was also studied by RNAi to PKA-Cα. cAMP
and cGMP significantly decreased PAFR binding and protein expression in normoxia
and hypoxia, more so in hypoxia, when PAFR expression was usually high. PKA-
Cα siRNA demonstrated that inhibition of PAFR-mediated responses by the cyclic
nucleotides occurred through PKA. These data suggest that the normally high levels
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of cyclic nucleotides in the normoxic newborn pulmonary circulation assist in the
downregulation of postnatal PAFR-mediated responses and that under hypoxic
conditions, increasing the levels of cyclic nucleotides will abrogate PAF-mediated
vasoconstriction thereby ameliorating PAF-induced persistent pulmonary hyperten‐
sion of the newborn.
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1. Introduction
Platelet-activating factor (PAF) is an endogenous phospholipid which evokes a wide range of
biological activities, such as vasoconstriction and systemic hypotension [1], mainly under
pathophysiological conditions. The discovery of PAF, its cellular origin, and biological actions
were first reported by Benveniste and Associates [2, 3]. Following these reports, investigations
of the physiological effects of PAF involved its roles in fetal lung maturation and lung function
[4-9], and its role in reproduction where it is involved in implantation of embryos, among other
effects [10, 11]. PAF produces a myriad pathological effects in vivo, including platelet aggre‐
gation [12-14], mediation of immune response and bronchoconstriction [15, 16], and smooth
muscle contraction [17-21], which hinges on its role as an inflammatory mediator and vaso‐
constrictor [17]. In the fetus, PAF plays an important physiological role in maintaining a high
level of vasomotor tone in the pulmonary circulation [22]. Therefore, the high PAF receptor
(PAFR) binding in fetal lamb lungs supports the existence of a high level of pulmonary
vasomotor tone in utero [23]. On the other hand, in lungs of the newborn lamb, PAFR binding
and receptor mRNA expression are low, suggesting a down regulation of PAFR-mediated
effects in vivo [22, 23].
PAF acts by binding to its Gq protein isoform of G protein-coupled receptors, which is a seven
transmembrane receptor [24]. Activation of G protein-coupled receptors by an agonist results
in activation of signal transduction pathways [25], which may involve recruitment of intra‐
cellular second messengers such as cAMP, cGMP, inositol 1,4,5-triphosphate (IP3), and calcium
[26, 27]. cAMP and cGMP act via their endogenous receptors, cAMP-dependent protein kinase
(cAMP/PKA) and cGMP-dependent protein kinase (cGMP/PKG), respectively, to elicit
relaxation of smooth muscle, and cAMP and cGMP mediate relaxation of pulmonary vessels,
but cGMP has been shown to be more effective than cAMP in producing relaxation of perinatal
ovine pulmonary vessels [28, 29]. Acute hypoxia upregulates PAFR-mediated intracellular
signaling in fetal ovine pulmonary vascular smooth muscle [30]. Chronic hypoxia in the
perinatal period may result in abnormal upregulation of PAFR protein expression, PAFR
binding, and PAFR-mediated cell signaling, leading to increased pulmonary vasomotor tone
and vascular remodeling, a key event in the onset of clinical disorders such as persistent
pulmonary hypertension of the newborn (PPHN) [31].
We are interested in understanding the mechanisms of pulmonary vascular relaxation at birth.
Our primary hypothesis is that with oxygenation at birth and the increased production of
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cAMP and cGMP in pulmonary vascular smooth muscle, PAFR protein expression and PAFR-
mediated cell signaling may be inhibited via cross-talk between the cyclic nucleotides and
PAFR-mediated responses. This hypothesis was investigated in ovine fetal pulmonary
vascular smooth muscle cells using cAMP and cGMP on PAFR binding and PAFR-mediated
cell signaling in both normoxia and hypoxia. After birth, during normoxia, pulmonary levels
of cAMP rise significantly, perhaps contributing to the decrease in PAFR binding, PAFR
protein expression and the ensuing fall in pulmonary vascular resistance. We employed siRNA
to the catalytic domain of PKA to define the role of PKA in decreased pulmonary PAFR-
mediated responses at birth.
2. Materials and methods
2.1. Materials
The study was approved by the Institutional Animal Care and Use Committee of Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center. Pregnant ewes (146-148 d
gestation, term being 150 d) were purchased from Nebekar Farms (Santa Monica, CA).
Authentic standards of PAF (C16-PAF) as well as 8-Br-cAMP, Rp-cAMPS, 8-Br-cGMP, Rp-8-
pCPT-cGMPS were purchased from Biomol, Plymouth Meeting, PA. Radiolabeled PAF
standards and substrates: hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, 1-O-[ace‐
tyl-3H-(N)]-, (3H-acetyl-C16-PAF), 21.5 Ci/mmol (370 GBq/mmol), and 3H-thymidine were
purchased from Perkin Elmer Life Sciences (Boston, MA). siRNA to PKA-Cα and its control
were purchased from Cell Signaling Technologies (Carlsbad, CA). Phenylmethysulfonyl
fluoride, leupeptin, pepstatin, as well as bovine serum albumin, were purchased from Sigma
Chemical Company (St. Louis, MO). Antibody to PKA and PKG were purchased from Cell
Signaling, while PAFR antibody was purchased from Cayman Chemical Company (Ann
Arbor, MI). Studies were done with freshly made reagents. Ecolite(+) liquid scintillation
cocktail was purchased from MP Biochemicals (Irvine, CA).
2.2. Methods
Arterial intrapulmonary vessels were isolated from freshly killed term fetal lambs and then
smooth muscle cells were harvested from the excised arteries and veins under sterile condi‐
tions as previously reported [20, 32]. Cells were used at the 3rd to 10th passage. Cell phenotype
did not change from 1st to 10th passage as determined by the expression of α-smooth muscle
actin and myosin light-chain kinase proteins.
2.3. Study conditions
Studies were done with adherent cells in normoxia and in hypoxia.
Normoxia: Cells were studied in humidified incubator at 37 °C aerated with 5% CO2 in air.
Hypoxia: An incubator set at 37 °C was first equilibrated for at least 1 h with a gas mixture of
2% O2, 10% CO2, and balance N2 to maintain incubator culture media pO2 < 40 Torr, and to
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mimic fetal lung environment, and monitored with TED 60T percent oxygen sensor, Teledyne
Analytical Instruments (City of Industry, CA). Cells were then placed in this equilibrated
incubator and continuously aerated with the hypoxia gas mixture throughout the duration of
the study.
2.4. Study of PAFR binding
2.4.1. General protocol
Receptor-binding assays were performed during hypoxia and normoxia as we previously
reported [30]. Briefly, after incubation in normoxia or hypoxia, unbound 3H-PAF was washed
off with ice-cold phosphate buffer saline, and then incubated on ice for 30 to 45 min in saline/
EDTA mixture containing 154 mM saline and 5 mM EDTA. Receptor bound 3H-PAF was
extracted on Whatman GF/C membrane filters using inline vacuum system. Then culture flasks
or dishes were washed with calcium-free 0.25% bovine serum albumin-containing Tyrodes
buffer, pH 6.4. Cell-bound PAF radioactivity was quantified by scintillation spectrometry
(Beckman Instruments, Fullerton, CA). In studies probing the interaction of PAF with its
receptors in the presence of other agonist or antagonists, cells were pre-incubated with the
agent before the addition of 3H-PAF, and then incubated further according to the specific
experimental protocol.
2.4.2. Specific protocols
Effect of cAMP/cGMP on PAFR binding: Cells were pre-incubated for 30 min, in normoxia or
hypoxia, with buffer for controls or 10 μM each of cell permeable cyclic nucleotide analogs, 8-
Br-cAMP or 8-Br-cGMP; the cAMP/PKA receptor inhibitor Rp-cAMPS or the cGMP/PKG
receptor inhibitor Rp-8-pCPT-cGMPS. Then 1.0nM 3H-PAF was added and incubated for 30
min more.
Effect of cAMP/cGMP on PAFR protein expression: Cells were pre-incubated for 3 hr min, in
hypoxia or normoxia, with buffer for controls or 10 μM each of cell-permeable cyclic nucleotide
analogs, 8-Br-cAMP or 8-Br-cGMP. Membrane proteins were isolated from cultured cells and
probed for PAFR protein expression by Western blotting.
Proliferation assay: Sub-confluent cells were serum starved by culturing in 0.1% fetal bovine
serum (FBS) for 72 hr, then cells were cultured in 10% FBS with or without the test agents in
the presence of 5μCi/well of 3H-thymidine and incubated for 24 hr more in the oxygen
condition [32]. Cell DNA that were labeled with 3H-thymidine were extracted with 0.5N NaOH
and quantified on LKB 6500 scintillation counter (Beckman Coulter, Fullerton, CA).
Transient cell transfection: Cells were seeded in 6-well culture plates at 5 × 104 cells per well in
an antibiotic-free growth media and allowed to stabilize for 24 h. Then they were treated with
1.5μg/ml of each plasmid in lipofectamine transfection reagent with 50nM of PKA-Cα siRNA
according to the vendor’s protocol (Cell Signaling) and incubated for 48 hr after which the
transfection medium was replaced with fresh 10% FBS culture medium, which was also used
to study cell proliferation or to study PAFR binding. Transfection efficiency was between 25%
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and 35% within 24 hr of transfection as judged by the pGFP fluorescence [32]. The proliferative
phenotype of transfected cells was compared to that of untransfected cells. In studying cell
proliferation or PAFR binding, transfected cells were incubated for 24 hr for proliferation study
or 30 min for PAFR binding, with and without 10nM PAF in 10% FBS. Control for cell
proliferation is 10% FBS alone while cells transfected with scrambled siRNA (sham siRNA)
were used as control for PKA-Cα siRNA effect.
2.5. Western blotting
Preparation of proteins for Western analysis: Proteins were prepared from stimulated and un-
stimulated cells that were studied in normoxia or hypoxia according to our previous reports.
Proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) Western blotting for PAFR quantification following our published methods [20, 30, 32,
33]. After x-ray exposure, band corresponding to PAFR protein was quantified and normalized
to β-actin density.
2.6. Data analysis
All numerical data are mean ± SEM. In all instances where radioisotope was used, background
radioactivity was subtracted before quantifying radioactivity. Data were analyzed with two-
tailed t-test followed with ANOVA (GraphPad Prism 6, San Diego, CA). Results were consid‐
ered significant at p < 0.05.
3. Results
Figure 1 shows the effect of 8-Br-cAMP and 8-Br-cGMP on PAF binding to its receptors in
pulmonary arterial smooth muscle cells (PASMC) (fmol/106 cells). For both 8-Br-cAMP and 8-
Br-cGMP, data are mean ± SEM, n = 6; *p < 0.05, different from normoxia; +p < 0.05, different
from PAF alone in normoxia or hypoxia. Cells treated with 10nM PAF alone, binding in
normoxia was 9.7 ± 1.0, which increased to 17.2 ± 1.0 in hypoxia. Pretreatment of cells with
10μM of 8-Br-cAMP decreased PAF by 31% in normoxia and by 29% in hypoxia, respectively.
Inhibition of endogenous cAMP effect with 1μM of the cAMP/PKA receptor inhibitor, Rp-
cAMPS in normoxia or hypoxia increased PAF binding by 65% compared to effect of PAF alone
in normoxia and by 35% compared to effect of PAF alone in hypoxia. Also, pretreatment of
cells with 10μM Br-cGMP decreased PAF binding by 38% and 40% in normoxia and hypoxia,
respectively, compared to the effect of PAF alone. Inhibition of endogenous cGMP activity
with the cGMP/PKG receptor antagonist Rp-8-pCPT-cGMPS (Rp-pCPT) increased PAF
binding by 20% compared to PAF alone in normoxia, and by 30% in comparison to binding
by PAF alone in hypoxia. In general, hypoxia increased PAFR binding; exogenous cAMP or
cGMP attenuated PAFR binding while inhibition of endogenous cAMP or cGMP activity with
specific cAMP/PKA or cGMP/PKG receptor antagonists restored PAFR binding to levels
higher than effect of PAF alone.
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Figure 1. Effect of cAMP and cGMP on PAF receptor binding FPASMC. Data are means ± SEM, n = 6. Cells were pre-
incubated for 30 min in normoxia or hypoxia with buffer alone, or 10μM of 8-Br-cAMP or 10μM of 8-Br-cGMP then
10nM PAF was added and incubated for 30 min more as described in the methods section. Hyoxia increased PAF re‐
ceptor binding and both 8-Br-cAMP and 8-Br.cGMP inhibited PAF receptor binding in normoxia and hypoxia. The
specific inhibitors of PKA and PKG signaling; Rp-cAMPs and Rp-8-pCPT-cGMP reversed inhibitory effects of 8-Br-
cAMP and 8-cGMP. *p <0.05, different from PAF normoxia; +p <0.05, different from PAF alone in normoxia or hypoxia.
Effect of cyclic nucleotides cAMP and cGMP on PAF stimulation of fetal pulmonary arterial
smooth muscle cells (FPASMC) growth (3H-thymidine DPM × 103) is shown in Figure 2. For
both 8-Br-cAMP and 8-Br-cGMP, data are mean ± SEM, n = 6, *p < 0.05, different from normoxia;
+p < 0.05, different from PAF alone in normoxia; #p < 0.05, different from PAF alone in normoxia
or hypoxia. Treatment of cells with 10nM of PAF in normoxia caused a 15% increase in cell
proliferation compared to effect of FBS control (55.9 ± 2.2). In hypoxia, PAF increased cell
proliferation by 25% compared to effect of FBS control in hypoxia (70.5 ± 8.4). Incubation with
10μM 8-Br-cAMP in normoxia or hypoxia produced no difference in cell proliferation com‐
pared to PAF effect in hypoxia (Figure 2a). However, co-incubation of cells with 10nM PAF in
the presence of cAMP significantly inhibited cell proliferation below effect of FBS control or
10nM PAF in normoxia and hypoxia. With cGMP (Figure 2b), treatment of cells with 10μM 8-
Br-cGMP in normoxia or hypoxia decreased cell proliferation by 40% in normoxia compared
to FBS control, and by 48% in compared to effect of 10nM PAF in normoxia. On the other hand,
8-Br-cGMP significantly increased cell proliferation compared to the effect of FBS control and
10nM PAF in hypoxia. Co-incubation of cells with PAF and 8-Br-cGMP in normoxia decreased
cell proliferation by 77% in compared to FBS control and by 80% compared to PAF alone. Co-
incubation with 8-Br-cGMP and PAF in hypoxia produced no significant difference in cell
growth compared to effects of FBS and 10nM PAF in hypoxia. Thus, cAMP and cGMP
produced different effects of PAF stimulation of FPASMC growth during normoxia and
hypoxia.
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Figure 3 shows representative Western blots of effect of cAMP and cGMP on PAFR protein
expression. For both 8-Br-cAMP and 8-Br-cGMP, data are mean ± SEM, n = 3. The statistics are
as shown in the figures. The figures are not meant to be a cross-comparison of the effects of 8-
Br-cAMP and 8-Br-cGMP on PAFR protein expression, but rather to compare effect of each
cyclic nucleotide on PAFR protein expression. However, the figures show that hypoxia
increased PAFR protein expression and in both cases, cAMP (Figure 3a) and cGMP (Figure
3b) decreased PAFR protein expression compared to control conditions.
Hanouni et al
Figure 2. Effect of cAMP and cAMP on PAF stimulation of FPASMC proliferation. Data are means ± SEM, n = 6. Cells
were pre-incubated for 30 min with buffer alone, or with 10 μM 8-Br-cAMP, or 10μM of 8-Br-cGMP, then PAF was
added and incubated for 24 hr more as described in methods section. PAF increased cell proliferation in normoxia and
hypoxia. Effect of 8-Br-cAMP on cell proliferation in normoxia or hypoxia, co-incubation of 8-Br-cAMP and PAF de‐
creased PAF-induced cell proliferation. 8-Br-cGMP alone decreased cell proliferation in normoxia, and co-incubation
with PAF further decreased PAF stimulation of cell proliferation. *p <0.05, different from normoxia; +p <0.05, different
from effect of 10% FBS; #p <0.05, different from PAF effect.
We then investigated the effect of PKA siRNA PAFR binding and PAF stimulation of FPASMC
proliferation in normoxia only. For both binding and proliferation, data are mean ± SEM, n =
6; *p < 0.05, different from 10% FBS control, +p < 0.05, different from PAF alone, #p < 0.05, different
from 10% FBS control, PAF alone, and 8-Br-cAMP (+cAMP). In Figure 4a, 8-Br-cAMP decreased
PAFR binding by 26% (PAF alone control, 10.2 fmol/106 cells). Pretreatment of cells with 50nM
of the PKA-Cα siRNA increased PAFR binding by 47% compared to effect of PAF alone
(control) and by 52% compared to effect of cAMP alone. The effect of sham PKA-Cα siRNA
(sham) was not different from PAF alone. In Figure 4b, PAF alone stimulated greater cell
proliferation (3H-thymidine DPM × 103) by 45% compared to 10% FBS control (101.2 ± 5.3).
Effect of 8-Br-cAMP on cell proliferation was 120.3 ± 7.8 which is 19% lower than effect of 10%
FBS control and 20% lower than effect of 10nM PAF alone. As with PAFR binding, PKA-Cα
increased cell proliferation and reversed the effect of cAMP on PAF binding. PAFR binding
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produced a 2-fold increase in cell proliferation compared to 10% FBS control and 37% increase
compared to effect of 10nM PAF. The effect of the sham siRNA control was not different from
effect of 10% FBS control.
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Figure 3. Effects of cAMP and cGMP on PAF receptor protein expression in normoxia and hypoxia. Data are means
±SEM, n= 3. Cells were incubated in for 24 hr in normoxia or hypoxia with buffer alone, or with 10μM of 8-Br-cAMP,
figure 3a, or with 10μM 8-Br-cGMP, figure 3b. PAF receptor (PAFR) expression was measureb by Western blotting and
normalized to expression of beta-actin standard. Rp-8-pCPT-cGMPS, then 5nM PAF was added as needed and incu‐
bated for 20 min more. Treatment of cell with 8-Br-cAMP or 8-Br-cGMP surpressed PAFR protein expression in nor‐
moxia and hypoxia. *p <0.05, different from control; +p <0.05, different from normoxia.
Hanouni et al
Figure 4. Effects of cAMP and and siRNA to PKA-cα on PAFR binding and PAF stimulation of cell proliferation. Data
are means ± SEM, n= 5. Studies were done as described in methods section. PAFR binding (figure 4a) and cell prolifera‐
tion were determined. PAFR binding was attenuated by 8-Br-cAMP, but siRNA to PKA-cα increased PAFR binding.
Effect of sham siRNA was not different from PAF alone. In figure 4b, 8-Br-cAMP decreased cell proliferation compared
to effect of PAF alone. siRNA to PKA cα increased cell proliferation. Effect of sham siRNA was not different from 10%
FBS or 8-br-cAMP. *p <0.05, different from PAF alone of 10% FBS control; +p <0.05, different from PAF alone; #p <0.05,
different from all other condition.
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4. Discussion
In fetal pulmonary circulation, vasomotor tone is maintained high by multiple mechanisms
such as elevated calcium, PAF, and thromboxane A2 [22, 34, 35]. At birth, endogenous
vasodilators induce smooth muscle relaxation via increased intracellular concentrations of the
cyclic nucleotides, cAMP and cGMP, acting through their respective receptors PKA and PKG
[27]. We have published previously that in ovine fetal pulmonary vascular smooth muscle
cells, hypoxia upregulates PAFR binding and PAFR-mediated intracellular IP3 and calcium
release [30], suggesting that the hypoxic environment of the fetus facilitates PAFR binding and
PAFR-mediated signaling and the maintenance of a high pulmonary vasomotor tone in utero.
The possibility that vasoconstrictors such as PAF may actively downregulate vasodilator
pathways in the hypoxic environment of fetal pulmonary circulation is being actively explored.
Similarly, the decreased PAFR-mediated activity in the higher oxygen environment of the
postnatal lung may involve the downregulation of PAFR-mediated cell signaling by other
endogenous mediators such as cAMP and cGMP [36, 37]. The present report investigates the
interaction between cyclic nucleotides, cAMP and cGMP, and PAF signaling pathway in
FPASMC. We have found that in ovine fetal pulmonary vascular smooth muscle cells, both
cAMP and cGMP decrease PAFR binding in normoxia through the actions of their respective
kinases, PKA and PKG. Addition of PAF in physiologic concentrations to pulmonary venous
smooth muscle cells decreased PKA and PKG protein expression and kinase activities during
normoxia and hypoxia, suggesting that in the hypoxic environment of the fetal lungs, PAF
may be actively downregulating cAMP- and cGMP-dependent signaling pathways and that
postnatally, in the normoxic environment, cAMP and cGMP actively inhibit PAF binding to
its receptors and PAFR-mediated signaling. This cross-talk between the two pathways will
effectively maintain a high pulmonary vasomotor tone in utero and facilitate vasorelaxation
at birth.
4.1. Cyclic nucleotides inhibit PAFR binding and PAFR-mediated cell proliferation
Role of cAMP: cAMP production is linked to β-adrenergic receptor-mediated activation of
adenylyl cyclase [38, 39]. Inhibition of cAMP- and cGMP-dependent phosphodiesterases
(PDEs) can also result in high cellular levels of cAMP and cGMP [38, 40], but the effect of cAMP
and cGMP on PAFR-mediated signaling in PASMC has not been reported. Unlike in pulmo‐
nary venous smooth muscle cells, the cell permeable analog of cAMP, 8-Br-cAMP, decreased
PAFR binding in normoxia and hypoxia. Inhibition of cAMP-dependent PKA, the endogenous
receptor of cAMP, with Rp-cAMPS, reversed the inhibitory effect of endogenous cAMP and
significantly increased PAFR binding. Also, when PKA was inhibited with Rp-cAMPS, PAF
binding in hypoxia was increased beyond the effect of addition of exogenous PAF alone. This
suggests that cAMP interacts with PAFR after activation of its own receptor, PKA.
Effect of cAMP downstream from PAFR in the nucleus of PASMC is not clear. 8-Br-cAMP
enhanced cell growth in normoxia, with no change in cell growth in hypoxia compared to PAF
effect in hypoxia. However, when cells were pulsed with 8-Br-cAMP and exposed to PAF, cell
proliferation was significantly decreased in normoxia and hypoxia, suggesting that cAMP
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effect occurs after activation of its receptor. This relationship is relevant physiologically
because it suggests that postnatally, cAMP will stimulate growth of PASMC and under this
condition, the presence of PAF will be detrimental cell growth and pulmonary vascular
development. Thus, we can speculate that cAMP/PKA-mediated inhibition of PAF effects, in
vivo, may constitute one mechanism whereby the postnatal vasodilator properties of cAMP
are maintained. Our studies with PKA siRNA demonstrate that cAMP acts at its receptor, PKA,
to inhibit postnatal adverse PAFR-mediated responses in the pulmonary circulation of the
newborn lamb lung.
Role of cGMP: Endothelium-derived nitric oxide produced under basal conditions, or by a
stimulus, readily diffuses into the contiguous smooth muscle to activate soluble guanylyl
cyclase, resulting in an increase in cGMP synthesis and smooth muscle relaxation [37, 38].
Nitric oxide is a potent vasodilator in the pulmonary circulation and it is important in the
transition of the pulmonary circulation from fetal to postnatal life. In this study, 8-Br-cGMP
blunted PAFR binding to PASMC in physiologic oxygen level (normoxia) and in hypoxia. This
suggests that cGMP produced in vivo will counteract the vasoconstricting properties of PAF.
Interestingly, inhibition of endogenous cGMP activity with the inhibitor of cGMP-dependent
PKG, the endogenous receptor of cGMP, resulted in abrogation of the ability of cGMP to inhibit
PAF binding to its receptors, similar to the effect of PKA receptor antagonist. This shows that
cGMP acts via its receptor to inhibit PAFR binding.
cGMP has been shown to inhibit endothelin-stimulated inositol phosphate release in pulmo‐
nary artery of fetal lambs studied in organ bath [41]. Inositol phosphate is released downstream
from PAFR effect. Both endothelin and PAF are potent endogenous vasoconstrictors in the
pulmonary circulation. This shows that increased levels of endogenous PAF under normoxic
conditions can inhibit cGMP effect and as a corollary, increased levels of cGMP after birth can
inhibit PAF effect in normoxia, leading to increased vasodilation. Our data show that cAMP
and cGMP produce different effects on cell proliferation. During normoxia, cGMP inhibited
PAF stimulation of cell proliferation, but the effect in hypoxia seemed to be stimulatory. This
physiological significance of this effect is not clear, but may indicate a protective role of cGMP
against unwarranted cell growth in the presence of PAF.
We can infer that in vivo, activation of PKA will result in inhibition of PAFR-mediated effects
such as stimulation of inositol phosphate release, calcium mobilization, and vasoconstriction.
As with cGMP effect, cAMP/PKA-mediated inhibition of PAF effects, in vivo, may constitute
one mechanism whereby the postnatal vasodilator properties of cAMP are maintained.
4.2. PAF and regulation of PKG and PKA activity and role in perinatal pulmonary adaptation
Previous reports have shown that the activities of PKG and PKA are upregulated by normoxic
condition [36, 37, 42]. The physiologic implications of these findings are that upregulation of
PKG and PKA activities by normoxia, after birth, is one mechanism by which fetal high
pulmonary vasomotor tone is downregulated to facilitate postnatal pulmonary adaptation. It
can be deduced that favorable perinatal pulmonary vascular adaptation can be achieved by
both downregulation of mediators of pulmonary vascular constriction, such as PAF, and
upregulation of mediators of pulmonary vasodilation such as cGMP/PKG and cAMP/PKA.
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Endothelin [43] and protein kinase C (PKC) [44] are two other mediators that have been
reported to evoke vasoconstriction in the perinatal pulmonary circulation. In this report, we
show that during normoxia, PAF significantly downregulates the activities of both cGMP- and
cAMP-dependent protein kinases. We also found that exposure of the smooth muscle cells to
8-Br-cAMP and 8-Br-cGMP for 30 hr in normoxia and hypoxia, resulted in significant down‐
regulation of PAFR in line with attenuation of PAFR binding to the cells. These findings
strongly indicate that congenial perinatal pulmonary adaptation entails a combination of
downregulation of PAFR-mediated effects by cyclic nucleotide-mediated pathways as we have
shown in this report, as well as by upregulation of cGMP- and cAMP-mediated pathways as
has been previously reported [31, 36, 37, 42].
PPHN is a pathological condition with different etiologies. High PAF levels have been reported
in neonates with PPHN [31, 45], suggesting that persistence of high PAF levels postnatally
may lead to abnormal perinatal pulmonary adaptation. In addition, we speculate that inhibi‐
tion of PKG and PKA activities by high levels of PAF and the inability of the cyclic nucleotides
to downregulate PAFR-mediated effects postnatally will also contribute to the development
of PPHN.
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